Details of the Drug Formulations

General Information of Drug (ID: DMSQLZJ)

• Drug Name: Nifurtimox Drug Info
• Synonyms: NIFURTIMOX; Lampit; Bayer 2502; 23256-30-6; BAY 2502; Nifurtimox [INN:BAN]; Nifurtimoxum [INN-Latin]; CCRIS 2201; EINECS 245-531-0; CHEBI:7566; C10H13N3O5S; 4-Thiomorpholinamine, 3-methyl-N-((5-nitro-2-furanyl)methylene)-, 1,1-dioxide; 4-((5-Nitrofurfurylidene)amino)-3-methylthiomorpholine-1,1-dioxide; 3-Methyl-N-[(5-nitro-2-furanyl)methylene]-4-thiomorpholinamine 1,1-dioxide; 3-Methyl-4-(5'-nitrofurylidene-amino)-tetrahydro-4H-1,4-thiazine-1,1-dioxide

Indication

Disease Entry	ICD 11	Status	REF
Chagas disease	IF53	Approved	[1]
Trypanosomiasis	1D51-1F53	Phase 4	[2]

• Cross-matching ID:
  PubChem CID: 6842999
  ChEBI ID: CHEBI:7566
  CAS Number: 23256-30-6
  TTD ID: D0FC1J
  VARIDT ID: DR01396
  ACDINA ID: D01282

Full List of Drug Formulations Containing This Drug

Nifurtimox 30 mg tablet

Company	Formulation ID	FDA Description
Bayer Healthcare Pharmaceuticals	F24093	Calcium Hydrogen Phosphate Dihydrate; Magnesium Stearate; Maize Starch; Silica Colloidal Anhydrous; Sodium Lauryl Sulfate

Nifurtimox 120 mg tablet

Company	Formulation ID	FDA Description
Bayer Healthcare Pharmaceuticals	F24094	Calcium Hydrogen Phosphate Dihydrate; Magnesium Stearate; Maize Starch; Silica Colloidal Anhydrous; Sodium Lauryl Sulfate

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [2] ClinicalTrials.gov (NCT00906880) Clinical Study to Assess the Tolerability, Feasibility and Effectiveness of Nifurtimox and Eflornithine (NECT) for the Treatment of Trypanosoma Brucei Gambiense HumanAfrican Trypanosomiasis (HAT) in the Meningo-encephalitic Phase. U.S. National Institutes of Health.